Large cap company Glaxosmithkline Pharmaceuticals Ltd. share today hit 20% upper circuit on Bombay Stock Exchange (BSE). Last trading price of Glaxosmithkline Pharmaceuticals shares on BSE stood at Rs 2332.25 per share with intraday gain of 15.59%. GSK Pharma share price zoomed 17.58% in last 2-weeks when Sensex slipped 1.52% due to subdued sentiment triggered by global trade uncertainty, regular foreign outflows, and moderate earnings posted by several firms.
Meanwhile, GSK share price has been witnessing stunning surge ever since it reported strong Q3FY25 results on February 14, 2025. It is worth mentioning that FII/FPI increased holdings from 4.36% to 4.50% for December 2024 quarter and FII/FPI investors rose from 337 to 347 for December 2024 quarter. The company has a market capitalisation of Rs 39,509.72 crore. Its return on equity (ROE) stood at 50.88%. Check more details below:
Glaxosmithkline Pharmaceuticals Q3 FY25 Results
The company on Feb 14 declared a sharp rally of 402% year-on-year (YoY) in its consolidated net profit to Rs 228.58 crore for the quarter ended December 2024 (Q3FY25) as against Rs 45.49 crore reported in the corresponding quarter of last year. Its revenue from operations witnessed gain of 17.5% YoY to Rs 946.36 crore in Q3FY25 as against Rs 804.98 crore declared in Q3FY24. The company’s strong performance led by its robust growth across key product portfolios.
Glaxosmithkline Pharmaceuticals Ltd Shares Performance
The 52-week high price of Glaxosmithkline Pharmaceuticals Ltd shares on BSE stood at Rs 3087.95 per share (as on 22/08/2024) and 52-week low price is Rs 1825.05 per share (as on 15/04/2024), respectively. Glaxo share price surged 13.09% in last 1-month, dived 19.75% in last 6-months, and surged marginally by 3.37% in last 1-year. In last 2-years, Glaxosmithkline Pharmaceuticals shares zoomed 87.82% and rose 77.24% in last 5-years.
Should You Buy GSK Shares?
A R Ramachandran, SEBI registered Independent research analyst said, “Glaxo Pharma stock price is bullish on the Daily charts with strong support at 2086. A Daily close above resistance of 2368 could lead to a target of 2618 in the near term.”
Meanwhile, ICICI Securities upgraded its estimates for the company’s FY25–26 earnings per share (EPS), to nearly 5% to 6% due to better margin outlook. The brokerage firm has add call with reduced target price of Rs 2,250 based on 38x FY26 estimates of earnings per share. Motilal Oswal also suggested buy call with target price of Rs 2,170 per share. The analyst also increased its earnings estimates for the pharma firm by 2%/5%/7% for FY25/FY26/FY27 to factor in a) differentiated launches in cancer therapy, b) scale-up of vaccine business, c) enhanced efforts to boost vaccine prospects.
Disclaimer: The stock has been picked from the brokerage report of AR Ramchandran, Motilal Oswal, and ICICI Securities. Moneydaily.in, the author, and the respective brokerage house will not be held accountable for any losses caused as a result of decisions based on the article. Moneydaily.in advises readers to do their own research or consult a SEBI registered investment advisor before making any investment decisions.
Recommended: 1675% Dividend Declared: ABB India Posts 56% Jump In Net Profit
Leave a Reply